Roflumilast, introduced in clinical practice two decades ago, is a phosphodiesterase 4 (PDE4) inhibitor that is well tolerated and approved for treating psoriasis and emphysema [162,163,164,165]. The gene discussed is PDE4A; the disease is pulmonary emphysema.